BioMarin Q3 2026 Revenue Jumps 32% to $1.025 Billion
BioMarin posted strong third-quarter results driven by surging metabolic and skeletal condition therapies, while updating full-year guidance amid order timing uncertainty.
BioMarin Pharmaceutical reported third-quarter 2026 total revenues of $1.025 billion, a 32% increase compared with the same period a year earlier, the company announced in its latest financial results disclosure.
The revenue surge was led by a 44% year-over-year jump in sales tied to metabolic conditions treatments, which outpaced the company's already-solid 12% growth in its skeletal conditions portfolio. Together, the two therapeutic segments drove the bulk of BioMarin's quarterly gains and underscored the company's expanding commercial footprint in rare disease markets.
Read more Starwood Capital, Trez Capital Form US Residential Land Finance Deal →
Despite the headline growth, BioMarin moved to update its full-year 2026 guidance, citing uncertainty around order timing as well as the financial impact of two acquired in-process research and development assets. Such adjustments are common when companies absorb acquisition-related charges that weigh on near-term profitability projections even as underlying product revenues remain robust.
The results highlight a broader trend among rare-disease-focused biotechs: strong top-line momentum can coexist with earnings-level pressure when pipeline investments and deal activity accelerate. Analysts will likely focus on whether BioMarin's metabolic franchise can sustain its elevated growth trajectory through the remainder of the fiscal year and into 2027.
Continue reading at All Financial Services & Investing.
